Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anifrolumab - Bristol-Myers Squibb/MedImmune

Drug Profile

Anifrolumab - Bristol-Myers Squibb/MedImmune

Alternative Names: Anti-IFNaR MAb - Medarex/MedImmune; MDX-1333; MEDI-546

Latest Information Update: 22 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medarex
  • Developer Medarex; Medical University of Vienna; MedImmune
  • Class Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interferon alpha beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Systemic lupus erythematosus
  • Phase II Lupus nephritis; Rheumatoid arthritis
  • Discontinued Scleroderma

Most Recent Events

  • 28 Dec 2018 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus(In volunteers) in USA (SC, Infusion)
  • 17 Dec 2018 AstraZeneca completes a phase II trial in Systemic lupus erythematosus in USA, Poland, Hungary and South Korea (NCT02962960)
  • 27 Sep 2018 AstraZeneca completes the phase III TULIP 2 trial in Systemic lupus erythematosus in USA, Spain, Lithuania, Argentina, Belgium, Brazil, Bulgaria, Canada, Czech Republic, France, Germany, Japan, South Korea, Mexico, Russia, Singapore and South Africa (IV) (NCT02446899) (EudraCT2014-004632-19)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top